Bio-Rad Wins 2020 Science Educators’ Best of Show Awards from the National Science Teaching Association for Educational Kits
HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that two of the company’s Bio-Rad Explorer Program science education products were presented with 2020 Science Educators’ Best of Show awards from the National Science Teaching Association (NSTA). Bio-Rad’s Out of the Blue CRISPR and Genotyping Extension kits were awarded “Best New Technology Innovation for Science” and the Science of Opioid Dependence Kit won in the category of “Best Tried & True Technology Teaching and Learning: Science & Social Impact.” Bio-Rad was also named a finalist for Outstanding Vendor.
The winners were selected by science educators who voted as NSTA members as well as a separate panel of judges. “The Bio-Rad Explorer Out of the Blue CRISPR and Genotyping Extension kits are complete curricula that begin with an amazing website [bio-rad.com/teachcrispr] that provides teacher resources,” remarked one of the judges. “Detailed instructions create a successful experiment for the students and the entire unit is well thought out, full of resources, and is at the cutting edge of genetic research and development.”
The Out of the Blue CRISPR and Genotyping Extension kits were launched in March. The kits provide hands-on gene editing hands-on activities and address the benefits and ethical issues associated with the procedure. CRISPR technology is a process that allows for the insertion, modification, and deletion of genes. For more information on the Out of the Blue CRISPR kits please visit bio-rad.com/outoftheblue.
The Science of Opioid Dependence Kit puts students in the roles of doctor and researcher as the students explore potential genetic links to opioid dependence. Students outline a human genetic research study as well as experiments to determine if a mutation in a patient’s human dopamine receptor gene may influence opioid dependence. They also consider environmental factors that contribute to dependence as a phenotype. For more information on the Science of Opioid Dependence kit please visit bio-rad.com/opioid.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Product Manager, Bio-Rad Explorer Program